Sofosbuvir

索磷布韦

Report date: 2026/03/31 20:00:21
NMEFirst In Class

Base Information

Drug NameSofosbuvir
Drug Alias Name索菲布韦HEPCINAT索非布韦HepcvirSofosbuvirum +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsLiver CirrhosisHypertension, PortalCarcinoma, Hepatocellular +[9] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2013/12/06
Country/TerritoryCzechiaCanadaUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland Uc
Inactive CompaniesGenuine Research Center, EgyptHannover Medical SchoolBenha University +[6] 
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsLiver CirrhosisHypertension, PortalCarcinoma, Hepatocellular +[7] 

Other Information

ATC CodeJ05AP08
Related LinksWikipediaDrugBankKEGG